Bryan Kay

6 POSTS 0 COMMENTS

Overtreatment in venous disease: Financial incentives are “the elephant in the...

To combat the “overtreatment problem” in the appropriate care of venous disease, “a concerted, complex, multimodal effort” is required from specialists across disparate parts...

AVF 2022: Emerging autogenous venous valve formation system sees “continual improvement”

An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual...

AVF 2022: Six-month CLOUT data indicate ClotTriever can effectively remove full...

Six-month outcomes from the ongoing CLOUT registry demonstrate the “safety and efficacy” of the ClotTriever thrombectomy system (Inari Medical) in a real-world deep vein...

AVF 2022: VenoValve improvement “maintained” for 2.5 years without adverse events

Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum...

Registry data show greater clot chronicity on postprocedure inspection than initially...

Nearly half of patients deemed preprocedurally to be suffering an acute case of deep vein thrombosis (DVT) turned out to have a “much more”...

Elder statesman of venous disease delivers golfing metaphor for fortitude, wellness

As a podium talk at the annual meeting of the American Venous Forum (VENOUS 2020; 3–6 March, Amelia Island, USA), it represented a bit...